Cancer clinical trial database.
Every new trial and trial result from New in Oncology, our weekly research briefing, since the first issue on . Search by NCT number, drug, or cancer type.
Latest entries
- New trial
Thyroid cancer
Phase 1/2 trial of 177Lu-DOTA-EB-TATE, somatostatin receptor directed beta emitter
This open-label study tests a three-dose regimen of 177Lu-DOTA-EB-TATE to assess safety, dosimetry, and efficacy in adults with metastatic, radioactive iodine non-responsive Hurthle cell thyroid cancer. Sponsored by…
NCT06991738 Exploratory - New trial
Ovarian cancer
Phase III Olaparib PARP Inhibitor Maintenance in Ovarian Cancer
This phase III trial compares one versus two years of maintenance olaparib—with or without bevacizumab—in patients with BRCA1/2-mutated or HRD+ stage III-IV ovarian cancer following first-line platinum-based…
NCT06580314 Registrational - New trial
Cervical and other gynecologic cancers
Phase 4 TIVDAK tissue factor–directed antibody-drug conjugate ocular safety trial
This study by Pfizer evaluates ocular side effects in patients with recurrent/metastatic cervical cancer post-chemotherapy. Eligible participants have no active eye issues and are TIVDAK-naïve, with scheduled eye…
NCT06952660 Exploratory - New trial
Cervical and other gynecologic cancers
Phase II Investigational HDR Brachytherapy (dose-adjusted internal radiotherapy) in cervical cancer.
This prospective non-randomized trial from Stanford University in Palo Alto evaluates a 3-fraction versus standard 4-fraction HDR brachytherapy regimen in locally advanced cervical cancer. Patients meeting dosimetric…
NCT07022470 Exploratory - New trial Spotlight
Prostate cancer
Phase 3 trial of Mevrometostat, an EZH2 inhibitor, with Enzalutamide in metastatic castration-sensitive prostate cancer
This randomized trial evaluates whether combining investigational Mevrometostat with enzalutamide improves outcomes for ARPI-naïve, chemo-naïve metastatic castration-sensitive prostate cancer patients compared to…
NCT07028853 Registrational - New trial
Prostate cancer
Phase 1b 177Lu-PSMA-617, PSMA directed beta emitter for mCRPC
This single-arm study at MD Anderson evaluates Lu-PSMA-617, administered IV every six weeks, for men with metastatic castration-resistant prostate cancer, PSA rise, bone marrow involvement, and cytopenia after…
NCT07025512 Exploratory - New trial
Prostate cancer
Phase 3 64Cu-SAR-bisPSMA PSMA-targeted imaging agent for recurrent prostate cancer
This study evaluates 64Cu-SAR-bisPSMA PET/CT for detecting prostate cancer recurrence in patients with prior prostatectomy, radiation, cryotherapy, or brachytherapy. Sponsored by Clarity Pharmaceuticals in Omaha, it…
NCT06970847 Registrational - New trial
Prostate cancer
Phase II: Darolutamide, Androgen Receptor Inhibitor in Prostate Cancer Neoadjuvant Study
This single-arm phase II trial by Icahn School of Medicine at Mount Sinai evaluates neoadjuvant ADT with leuprolide, darolutamide, and pembrolizumab followed by adjuvant pembrolizumab in NCCN high-risk non-metastatic…
NCT07027124 Exploratory - New trial
Prostate cancer
Phase 2 trial of relugolix, a GnRH receptor inhibitor improving PSMA PET/CT sensitivity.
This Phase 2 randomized study by Mayo Clinic evaluates short-course relugolix (administered for 5, 10, or 15 days) to boost PSMA expression and enhance PET/CT imaging in high/very high risk prostate cancer patients…
NCT07025369 Exploratory - New trial
Bladder and urothelial cancer
Phase 2 TYRA-300 FGFR3-directed mAb trial
This open-label study at Nashville evaluates TYRA-300 monotherapy in patients with FGFR3-altered, low grade, intermediate risk non-muscle invasive bladder cancer. The trial features dose-finding cohorts sponsored by…
NCT06995677 Exploratory - New trial
Bladder and urothelial cancer
Phase 2 study V940 personalized mRNA vaccine for patient-specific cancer immune targeting
This Phase 2 study evaluates whether combining V940 with standard BCG extends event-free survival compared to BCG alone, as well as the efficacy of V940 monotherapy in high-risk non-muscle invasive bladder cancer.…
NCT06833073 Exploratory - New trial
Liver and bile duct cancer
Phase 1 trial: Tremelimumab, CTLA-4 directed mAb combined with radiotherapy for HCC
This Phase 1 study tests a preoperative protocol combining three fractions of focused radiotherapy with one dose of Tremelimumab followed by Durvalumab every four weeks, in patients with resectable or advanced…
NCT06994299 Exploratory - New trial
Stomach and esophageal cancer
Phase 1 vvDD-hIL2: Oncolytic vaccinia virus with IL2 expression
This Phase 1 study evaluates vvDD-hIL2 administered via intra-tumoral injection to determine optimal dose and safety in patients with metastatic gastrointestinal and peritoneal tumors (MSI-H and MSS) at AHN West Penn…
NCT07001592 First-in-human - New trial
Colorectal cancer
Phase 2 trial: BMS-986340, a CCR8-targeting antibody, in advanced microsatellite-stable colorectal cancer
The study evaluates a single‐arm regimen combining BMS-986340, nivolumab, trifluridine/tipiracil, and bevacizumab for patients with advanced or metastatic refractory microsatellite-stable colorectal cancer. Conducted…
NCT07011550 Exploratory - New trial
Head and neck cancer
Phase II Pilot: SCRT – hypofractionated radiation for high-risk cSCC local control
This Phase II trial evaluates whether five-fraction SCRT offers effective local control for adults with head and neck cutaneous squamous cell carcinoma and if active surveillance is a safe alternative in…
NCT06998342 Exploratory - New trial
Brain and CNS tumors
Phase 1 trial: Dasatinib tyrosine kinase inhibitor for residual glioma
This Phase 1 trial led by Mayo Clinic in Rochester evaluates safety, tolerability, and potential efficacy of sequential combination regimens – starting with dasatinib plus quercetin, fisetin, and temozolomide – in…
NCT07025226 Exploratory - New trial Spotlight
Neuroendocrine and adrenal tumors
Phase Ib/II ZL-1310: DLL3-targeted Topoisomerase I inhibitor in selected solid tumors.
This multi-center, open-label trial from Zai Lab (Shanghai) is assessing ZL-1310 as a single-agent therapy in patients with neuroendocrine carcinomas progressing after platinum therapy. The study is conducted at…
NCT06885281 Exploratory - New trial
Neuroendocrine and adrenal tumors
Phase 1 study of naxitamab GD2-directed monoclonal antibody in neuroblastoma
This trial uses a modified 3+3 design to assess the optimal naxitamab infusion duration with irinotecan, temozolomide, and sargramostim in patients with relapsed or refractory neuroblastoma or ganglioneuroblastoma.…
NCT07027748 Exploratory - New trial
Neuroendocrine and adrenal tumors
Phase 2/3 Zanzalintinib Trial: cMet/VEGFR inhibitor in Neuroendocrine Tumors
This multicenter, randomized open-label study sponsored by Exelixis compares daily oral zanzalintinib to everolimus in patients with previously treated, unresectable locally advanced or metastatic neuroendocrine…
NCT06943755 Exploratory - New trial
Neuroendocrine and adrenal tumors
Phase 1 trial of PHOX2B PC-CAR T, a PHOX2B-directed CAR-T therapy
This first-in-human dose escalation trial uses a standard 3+3 design to determine the maximum tolerated dose in patients with relapsed or refractory high‐risk neuroblastoma. The study, led by Stephan Grupp MD PhD in…
NCT07007117 First-in-human - New trial
Neuroendocrine and adrenal tumors
Phase 3 trial of [177Lu]Lu-DOTA-TATE, a somatostatin receptor-targeted radioligand therapy.
This study evaluates the efficacy and safety of [177Lu]Lu-DOTA-TATE plus octreotide LAR versus octreotide LAR alone as first-line treatment in newly diagnosed patients with well-differentiated, somatostatin receptor…
NCT06784752 Registrational - New trial Spotlight
Multiple myeloma
Phase 2 teclistamab bispecific BCMA/CD3 antibody trial in high-risk multiple myeloma
This open-label Phase 2 trial investigates sequencing of teclistamab, daratumumab, and talquetamab—with or without melphalan transplant—for newly diagnosed high-risk multiple myeloma patients stratified by minimal…
NCT07029776 Exploratory - New trial
Multiple myeloma
Phase 2 linvoseltamab: BCMA and CD3 bispecific antibody
This phase 2 study evaluates the safety and efficacy of linvoseltamab in multiple myeloma patients relapsed after BCMA CAR T-cell therapy. All subjects receive an initial inpatient step-up dosing regimen followed by…
NCT07009899 Exploratory - New trial
Multiple myeloma
Phase 1/2 Belantamab Mafodotin, a BCMA-targeted tubulin inhibitor ADC study
This trial evaluates escalating doses of belantamab alone or combined with belantamab mafodotin for relapsed/refractory multiple myeloma patients (≥4 prior therapies). Sponsored by GlaxoSmithKline, the multicentre…
NCT05714839 Exploratory - New trial
Lymphoma
Phase 2 pembrolizumab PD-1 inhibitor with GVD consolidation in relapsed/refractory Hodgkin lymphoma
This Phase 2, open-label study evaluates pembrolizumab plus GVD consolidation in relapsed or refractory classic Hodgkin lymphoma patients with prior doxorubicin use. FDG-PET/CT imaging and Foresight CLARITY liquid…
NCT07021989 Exploratory - New trial
Lymphoma
Phase 2 Brentuximab Vedotin ADC, a CD30-targeted tubulin inhibitor.
This trial at the University of Miami evaluates the efficacy and safety of the abbreviated BrECADD regimen in patients with Stage 2B-4 Hodgkin Lymphoma. An exploratory objective is to assess circulating tumor DNA as…
NCT07002216 Exploratory - New trial
Lymphoma
Phase 1b glofitamab CD20/CD3 bispecific mAb for frontline DLBCL in older adults
This study evaluates a combination treatment using glofitamab with polatuzumab, obinutuzumab, and R-miniCHP for untreated patients (65+) with DLBCL, HGBCL, or transformed lymphoma. A response-adapted design based on…
NCT06765317 Exploratory - New trial
Lymphoma
Phase Ib Loncastuximab Tesirine (anti-CD19 ADC) and Roflumilast (PDE4 inhibitor) in High-Risk DLBCL
This Phase Ib single-arm trial evaluates a combination of Loncastuximab Tesirine, Roflumilast, and standard R-CHOP in newly diagnosed high-risk diffuse large B-cell lymphoma. The study, led by The University of Texas…
NCT06977711 Exploratory - New trial
Lymphoma
Phase I alectinib (ALK kinase inhibitor) plus duvelisib (PI3K delta-gamma inhibitor) dual-target trial
This study evaluates the safety and efficacy of alectinib lead-in followed by duvelisib combination to establish tolerable doses in relapsed/refractory ALK+ anaplastic large cell lymphoma. Conducted by Memorial Sloan…
NCT07001384 Exploratory - New trial
Lymphoma
Phase 2 Nivolumab Checkpoint Blockade in Relapsed/Refractory ALK+ ALCL
This trial evaluates risk-adapted chemommunotherapy—with Nivolumab and tailored chemotherapy potentially followed by an allogeneic stem cell transplant—in children, adolescents, and young adults with…
NCT07013565 Exploratory
Looking for trials that fit a specific diagnosis? Read our guide on how to find a clinical trial, or subscribe to New in Oncology to get each issue by email.